Trexquant Investment LP Autolus Therapeutics PLC Transaction History

Trexquant Investment LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$3.52 - $5.46 $63,205 - $98,039	-17,956 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.1 - $7.0 $91,575 - $125,692	17,956 New	17,956 $93,000
Q3 2021 Nov 12, 2021	SELL	$5.32 - $7.37 $220,099 - $304,911	-41,372 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$4.78 - $7.96 $197,758 - $329,321	41,372 New	41,372 $275,000
Q4 2020 Feb 11, 2021	SELL	$8.13 - $12.79 $151,591 - $238,482	-18,646 Closed	0 $0
Q3 2020 Nov 06, 2020	SELL	$11.64 - $16.3 $297,367 - $416,416	-25,547 Reduced 57.81%	18,646 $217,000
Q2 2020 Aug 07, 2020	BUY	$5.38 - $16.14 $237,758 - $713,275	44,193 New	44,193 $708,000

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $205M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.